Science AI Journal
Neuroscience · Research topic

Open research questions in Tryptophan and brain disorders

78 unresolved questions extracted from the limitations and future-work sections of 482 Tryptophan and brain disorders papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Finally, in view of the existing research limitations, the key research directions that need to be explored in the future are clarified, providing evidence-based basis and viewpoint references for promoting the precise prevention and control and clinical management optimization of depression after cerebral hemorrhage.

    Multidimensional risk network and clinical management of depression after intracerebral hemorrhage · 2026 · DOI

  • Importantly, whether DAAO inhibition can improve therapeutic outcomes in SCZ by increasing d -amino acid levels remains to be further validated.

    NMDA receptor modulators – d-amino acids’ pathophysiological roles and therapeutic potential in schizophrenia · 2026 · DOI

  • , 2026), we acknowledge that the lack of a concurrent positive control group in the present study is a major limitation affecting efficacy benchmarking. Future surface plasmon resonance or isothermal titration calorimetry experiments are warranted to experimentally validate these interactions and determine accurate binding constants.

    Intestinal microbial remodeling and metabolite regulation may be related to the improvement of social avoidance in depressed mice by Modified Xiaoyaosan · 2026 · DOI

  • 22 Third, the use of peripheral BDNF as a proxy for central neurobiological processes represents an important limitation. In particular, dose– response relationships between exercise intensity and BDNF response remain insufficiently characterized and represent a critical gap in current knowledge.

    Exercise-induced BDNF signaling mediates neuroplasticity in depression · 2026 · DOI

  • Data analyses included dimensionality reduction, regression models, correlation analysis, functional enrichment, and factor analysis of mixed data with k-means clustering, including 72 symptom-related items, lifestyle, and socioeconomic scales.

    Untargeted plasma proteomics and clinical phenotypes in adolescent depression · 2026 · DOI

  • Here we investigated whether these positive neural effects of TMAO extended to humans, analysing how TMAO exposure associates with neurodevelopmental outcomes in children and whether an in vitro human neuronal-astrocyte co-culture could contribute to further investigation of the underlying mechanism(s) and neuronal processes related to these associations.

    Integrated epidemiology and toxicology reveals the protective effects of TMAO against chemical neurotoxicity in children · 2026 · DOI

  • Notably, 9,10-DiHOME is reported for the first time in the context of differential regulation in human follicular fluid under distinct ART protocols, warranting further investigation as a potential marker of follicular metabolic adaptation.

    Differences in follicular fluid kynurenic acid and 9,10-DiHOME levels between controlled ovarian stimulation and modified natural ART cycles · 2026 · DOI

  • While its exact enzymatic origin remains unclear, Quinaldic acid is thought to arise from an alternative oxidative transformation of Kynurenine22.

    Differences in follicular fluid kynurenic acid and 9,10-DiHOME levels between controlled ovarian stimulation and modified natural ART cycles · 2026 · DOI

  • However, the biological consequences of this IL-34 mutation in humans, its prevalence in the population, and the mechanisms by which IL-34-Y213X alters microglial homeostasis, cerebrospinal fluid (CSF) proteomic networks, and amyloid pathology remain poorly understood.

    Human IL-34 Deficiency Primes Microglia Toward Alzheimer's Disease-Associated States · 2026 · DOI

  • This study has several notable strengths. First, we employed a rigorous approach to stratify participants by HIV and marijuana use, allowing for a nuanced assessment of their associations with peripheral inflammation and cognition. Second, we used a comprehensive panel of peripheral bio- markers spanning multiple immune pathways, enhancing the biological interpretability of results. Third, we incorporated demographically adjusted T scores from validated neuro- psychological instruments across multiple domains. Limita- tions include the cross-sectional design, which limits causal inference about relationships between biomarkers, cogni- tive function, chronic HIV disease, and marijuana use. Gen- eralizability may be constrained by the geographic region and sample characteristics, including a predominance of male and Black/African American participants. It may also be limited by the clinical profile of the HIV sample, as all PWH were virally suppressed on cART and had mean CD4 counts within the normal range, and thus may not reflect individuals with unsuppressed viremia or greater immuno- suppression. Marijuana exposure was assessed using a com- bination of self-report, urine drug screening, and circulating cannabinoid levels; however, use was not standardized with respect to dose, potency, or route of administration, which may introduce measurement variability and limit inference regarding specific patterns of use. Finally, most participants used THC-dominant products, suggesting that immunologic effects observed here are primarily attributable to THC exposure rather than balanced THC/CBD formulations.

    Neuroimmune Correlates of HIV and Marijuana Use: Peripheral Biomarkers and Cognitive Function · 2026 · DOI

  • The etiology and course of depressive disorder is complex, multilayered and remains poorly understood today, with the current nosological concept failing to provide sufficient guidance for effective pharmacotherapy. Depression is multifaceted, there is no consensus on the definition of biomarkers, and the transfer of discoveries from the laboratory setting to clinical use remains difficult.

    ROLE OF NEUROINFLAMMATION IN DEPRESSION AND ANTIDEPRESSANT DRUG DEVELOPMENT: EMERGING INSIGHTS AND THERAPEUTIC PERSPECTIVES · 2026 · DOI

  • Background: ARTICLE IN PRESS ARTICLE IN PRESS ACCEPTED MANUSCRIPT Antipsychotic-related erectile dysfunction (APRED) may represent a clinically significant yet poorly understood biological vulnerability in a subset of male patients with schizophrenia, rather than a simple pharmacological side effect.

    Serum proteomic signatures and an immune-calcium signaling cascade associated with antipsychotic-related erectile dysfunction in schizophrenia · 2026 · DOI

  • Changmaxifeng granules (CG), a traditional Chinese medicine formulation, have demonstrated promising clinical results in managing TDs; however, their pharmacodynamic basis and mechanisms of action remain poorly understood.

    Integrating traditional Chinese medicine and modern technology: A new approach to understanding Changmaxifeng granules for tic disorders · 2026 · DOI

  • Serum S100B levels were elevated during the acute phase of MDD with suicidal ideation and decreased following treatment; however, the specificity of this longitudinal change to suicidality could not be determined within the present study design.

    Serum S100B and Suicidal Ideation in Major Depressive Disorder: Evidence for a Trauma-Mediated Neurobiological Pathway · 2026 · DOI

  • Although the present study provides relevant evidence of early behavioral and glial alterations induced by OBX, several limitations should be acknowledged. First, while detailed quantitative and morphometric analyses of astro- cytes and microglia were performed using Sholl-based approaches, the study did not incorporate functional or molecular markers of glial activity, such as inflammatory cytokine profiles, metabolic state indicators, or gene expres- sion analyses. Given that glial cells can undergo substantial functional modulation in the absence of overt morphological remodeling, particularly during early or low-grade activa- tion states, it is possible that functional alterations occurred that were not captured by the morphometric methodologies employed. In addition, the experimental design was restricted to a single sex, which limits the generalizability of the findings. Accumulating evidence indicates that sex-specific differ- ences exist in stress responsivity, glial activation dynam- ics, and vulnerability to affective disorders, with males and females often exhibiting distinct neuroimmune trajectories and behavioral phenotypes. Consequently, it will be impor- tant to conduct future studies that incorporate sex as a bio- logical variable to determine the extent to which the early glial and behavioral changes observed here are conserved or diverge between sexes. Given the exploratory and hypoth- esis-generating nature of several analyses in this study, we did not apply a formal multiple-comparisons correction across all tests.

    Early-stage olfactory bulbectomy induces hyperlocomotion with increased astrocyte and microglial density in the prefrontal cortex of male rats · 2026 · DOI

  • This study highlights DYM's role but has limitations. The molecular mechanisms by which DYM affects Golgi structure and the NLRP3 inflammasome need clarification, including whether DYM directly interacts with inflammasome components or influences them via membrane trafficking. The cell-type specificity of DYM's effects, beyond microglial activation, should be studied, as it may also impact astrocytes and neurons. Additionally, understanding the upstream regulators of DYM expression, such as the impact of chronic stress and potential involvement of glucocorticoid signaling or epigenetic mechanisms, is important. Translational research should examine if DYM levels change in MDD patients and their correlation with symptoms or treatment outcomes.

    The role of Dymeclin in chronic unpredictable mild stress-induced depression: maintaining the Golgi apparatus structure and regulating NLRP3 inflammasome activation · 2026 · DOI

  • This study profiled a single disease stage (clinical score ≈ 2). Longitudinal sequencing and physiology will be required to map the temporal sequence from immune activation to hypo−excitability. In addition, sex−specific effects were not explored and warrant investigation given known differences in MS prevalence and PTSD vulnerability. In sum, our work delineates a convergent immune–excitability mechanism that compromises dorsal hippocampal CA1 function and sustains persistent fear in EAE. By integrating electrophysiology, single-cell genomics and circuit-specific rescue, we provide a coherent framework linking neuro-immune signaling to behavioral pathology and identify candidate targets for therapeutic intervention.

    Hippocampal neuronal hypoexcitability contributes to PTSD-like phenotypes in the experimental autoimmune encephalomyelitis model · 2026 · DOI

  • Schizophrenia (SCZ) is a highly heterogeneous mental dis- order that would cause severe clinical damages and heavy economic burden, however the underlying mechanisms of SCZ has needed to be addressed, which still remains unclear. These findings may point to underlying biological mechanisms that warrant further investigation.

    Machine learning-based integration identifies a 10-gene predictive signature and its classification patterns in schizophrenia · 2026 · DOI

  • Evidence supporting sphingolipid involvement in MDD pathophysiology has grown substantially, with the ASM/ceramide system emerging as an important therapeutic target. Antidepressants from multiple pharmacological classes may influence sphingolipid 10 N. HOERTEL et al. metabolism through different mechanisms. Some act directly as FIASMAs—reducing membrane ceramide and inducing autophagy via ER ceramide accumulation in preclinical models—while others may do so indirectly, via anti-inflammatory effects that reduce TNF-α–driven ASM activation, or through autophagy induction by pathways that may intersect with sphingolipid signaling. This mechanistic convergence is consistent with sphingolipid dysregulation functioning as a potential mediating node across major pathophysiological pathways in MDD— monoaminergic signaling, neuroinflammation, neurogenesis and apoptosis, mitochondrial function, glutamatergic signaling, and synaptic plasticity—and as a common pathway through which risk factors—including stress, genetic vulnerability, and metabolic dysfunction—may contribute to depression pathophysiology. Importantly, the relative contribution of each mechanism may vary across patients and across episodes in the same patient, which may help explain MDD’s biological heterogeneity. This integrative positions the sphingolipid system as a potential mechanism linking previously disparate findings in MDD research, though this hypothesis requires further investigation. Multiple lines of evidence support potential causal involvement of sphingolipids in MDD. Clinical studies consistently demonstrate altered ceramide profiles in depression [40, 41], though a systematic review noted heterogeneity suggesting subgroup variations. Animal studies demonstrate temporal precedence, with sphingolipid changes preceding depressive behaviors [74, 75, 86] and dose-response relationships, though human longitudinal confirmation is needed. Biological plausibility is further supported by experimental evidence: pharmacological or genetic manipulation of sphingolipid metabolism affects depressive behaviors in animals [11, 76, 77, 79], while antidepressants modulate sphingolipid profiles [19, 134]. Collectively, this evidence suggests that sphingolipid dysregulation may contribute meaningfully to MDD pathogenesis through complex, multifaceted mechanisms, offering diverse therapeutic opportunities. Despite accumulating evidence, several important limitations and gaps must be acknowledged. First, the specific ceramide likely reflecting patient species implicated vary across studies, heterogeneity, methodological differences, or distinct MDD subtypes. In addition, most clinical studies examine peripheral blood sphingolipids, and whether peripheral measurements reflect brain sphingolipid metabolism remains unclear. Notably, Schumacher et al.

    The role of sphingolipids in major depressive disorder and associated cognitive impairment: interactions with monoaminergic signaling, neuroinflammation, and neurogenesis · 2026 · DOI

  • The paper calls for standardization of herbal preparations, rigorous experimental design, and shared data platforms to enable reproducible science in integrated TCM-Western medicine therapy for depression, but does not specify standards for bioactive compound quantification, extraction protocols, or data repository infrastructure needed.

    Management of depression utilizing Traditional Chinese Medicine · 2026 · DOI

  • AI-driven network pharmacology approaches are proposed to predict botanical drug-metabolite-target interactions and inform rational combination strategies for TCM and Western antidepressants, but no specific implementation framework, training datasets, or validation protocols for these predictions in depression treatment are currently detailed.

    Management of depression utilizing Traditional Chinese Medicine · 2026 · DOI

  • The paper identifies purinergic signaling (P2X7, NLRP3/Caspase-1/GSDMD, adenosine A2A receptors) as a key integrative hub in depression, but lacks empirical testing of whether TCM agents genuinely modulate these defined neurobiological pathways or whether observed benefits are attributable to non-specific effects, expectancy bias, or methodological limitations in current preclinical studies.

    Management of depression utilizing Traditional Chinese Medicine · 2026 · DOI

  • Non-pharmacological TCM modalities such as acupuncture and herbal baths are clinically promising for depression symptom relief but demand deeper mechanistic scrutiny, including reproducibility of neurochemical changes and determination of pharmacokinetic profiles of active agents in these delivery systems.

    Management of depression utilizing Traditional Chinese Medicine · 2026 · DOI

  • The paper hypothesizes that specific TCM agents (saikosaponin D, salidroside, CHSGS) may modulate P2X7/NLRP3-driven neuroinflammation and restore astrocyte-dependent ATP dynamics, but these hypotheses require testing via multi-omics profiling (transcriptomics, metabolomics, microbiome) to map system-wide impacts of TCM intervention in depressive phenotypes.

    Management of depression utilizing Traditional Chinese Medicine · 2026 · DOI

  • Many existing studies on TCM herbal extracts fail to define the precise bioactive metabolites, confirm direct target engagement at molecular receptors, or genetically validate mechanistic pathways. Studies must employ cell-type-specific knockout models (e.g., P2X7R in microglia) and chemogenetic/optogenetic approaches to establish necessity of key signaling nodes in depression pathways.

    Management of depression utilizing Traditional Chinese Medicine · 2026 · DOI

Most-cited papers in Tryptophan and brain disorders

Most recent work

Find a gap in your own Tryptophan and brain disorders sub-topic

This page shows what the Tryptophan and brain disorders literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Neuroscience

Autism Spectrum Disorder Research
687 open questions
Neural and Behavioral Psychology Studies
178 open questions
Functional Brain Connectivity Studies
148 open questions
Memory Processes and Influences
136 open questions
Hearing Loss and Rehabilitation
131 open questions
Neurobiology of Language and Bilingualism
116 open questions
Psychology of Moral and Emotional Judgment
115 open questions
Neuroinflammation and Neurodegeneration Mechanisms
106 open questions
78 open questions have been extracted from the limitations and future-work passages of 482 Tryptophan and brain disorders papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.